Luis G. D'marco

Valencia, VC, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 72 publications

Anesthetic risk, mitochondrial variants and genetic ancestry: The need for proportionality in emerging evidence.

Anesthetic risk, mitochondrial variants and genetic ancestry: The need for proportionality in emerging evidence.

Journal: Journal of clinical anesthesia

Published: April 16, 2026

Depot-Specific Cardiorenal Adipose Remodeling with SGLT2i in Chronic Kidney Disease.

Depot-Specific Cardiorenal Adipose Remodeling with SGLT2i in Chronic Kidney Disease.

Journal: Journal of clinical medicine

Published: April 08, 2026

Correction: SGLT2 inhibitors and their role in reducing adiposopathy and inflammation in diabetes and non-diabetes CKD patients.

Correction: SGLT2 inhibitors and their role in reducing adiposopathy and inflammation in diabetes and non-diabetes CKD patients.

Journal: International urology and nephrology

Published: February 16, 2026

Preliminary Real-World Experience with Semaglutide in Obese Patients with Type 2 Diabetes on Chronic Hemodialysis: A Multicenter Pilot Study.

Preliminary Real-World Experience with Semaglutide in Obese Patients with Type 2 Diabetes on Chronic Hemodialysis: A Multicenter Pilot Study.

Journal: Medicina (Kaunas, Lithuania)

Published: December 26, 2025

Glucagon-like Peptide Receptor Agonists and Kidney Outcomes in the Era of Personalized Medicine: Focus on Albuminuria.

Glucagon-like Peptide Receptor Agonists and Kidney Outcomes in the Era of Personalized Medicine: Focus on Albuminuria.

Journal: Journal of personalized medicine

Published: December 12, 2025

SGLT2 inhibitors and their role in reducing adiposopathy and inflammation in diabetes and non-diabetes CKD patients.

SGLT2 inhibitors and their role in reducing adiposopathy and inflammation in diabetes and non-diabetes CKD patients.

Journal: International urology and nephrology

Published: October 31, 2025

Molecular mechanisms linking adipose tissue browning to reduced cardiovascular risk.

Molecular mechanisms linking adipose tissue browning to reduced cardiovascular risk.

Journal: Atherosclerosis

Published: September 06, 2025

C-peptide and epicardial adipose tissue in dialysis-dependent chronic kidney disease patients.

C-peptide and epicardial adipose tissue in dialysis-dependent chronic kidney disease patients.

Journal: Frontiers in medicine

Published: June 20, 2025

SGLT2 Inhibitors: Multifaceted Therapeutic Agents in Cardiometabolic and Renal Diseases.

SGLT2 Inhibitors: Multifaceted Therapeutic Agents in Cardiometabolic and Renal Diseases.

Journal: Metabolites

Published: June 06, 2025

Novel Pathogenic Genotype in SLC12A3 Associated to Gitelman Syndrome: A Case Report.

Novel Pathogenic Genotype in SLC12A3 Associated to Gitelman Syndrome: A Case Report.

Journal: Nephrology (Carlton, Vic.)

Published: February 24, 2025

Perirenal fat differs in patients with chronic kidney disease receiving different vitamin D-based treatments: a preliminary study.

Perirenal fat differs in patients with chronic kidney disease receiving different vitamin D-based treatments: a preliminary study.

Journal: BMC nephrology

Published: November 19, 2024

Evaluating Osteoporosis in Chronic Kidney Disease: Both Bone Quantity and Quality Matter.

Evaluating Osteoporosis in Chronic Kidney Disease: Both Bone Quantity and Quality Matter.

Journal: Journal of clinical medicine

Published: December 30, 2023

Showing 1-12 of 72

Last Updated: 09/26/2026